Industry Insights

31. Tackling Special Characters With SAS And R 9/3/2025

    Protect the integrity of your research by proactively detecting and removing hidden characters to ensure accurate, reliable, and compliant study results.

32. Ocular Endpoint Protection In A Capital-Constrained Market 9/3/2025

    Ocular Endpoint Protection reframes data capture as a non-negotiable driver of efficiency, and sponsors who embed point-of-need (PON) into their protocols protect both their investment and results.

33. Scout Belongs In Your eClinical Solution Suite 9/3/2025

    Traditional eClinical platforms manage data, but not participation. Learn how to fill the gap with travel, payments, and support that keep patients engaged, sites focused, and trials moving forward.

34. The Hidden Cost Of Transactional Burden: It's Time For Sites To Speak Up 9/3/2025

    Transactional burdens weigh heavily on sites, straining trust with sponsors and patients. See why site voices matter and how sounding off can strengthen clinical trial relationships.

35. Global Trials Can't Afford To Overlook Africa 9/3/2025

    Africa’s trial capacity is growing, but patient services remain the key to retention and reliable outcomes. Sponsors that act now can shape Africa into a true global trial hub.

36. Navigating Autoimmune Disease A Playbook For Cell And Gene Therapies 9/3/2025

    By integrating site readiness, patient engagement, and data-driven decision-making, the cell and gene therapies (CAGT) field is advancing toward therapies that not only control disease but transform lives.

37. Five Questions Biotechs Should Ask Before Selecting A Bioanalytical CRO 9/2/2025

    In a landscape where speed, quality, and trust are inseparable, choosing a CRO that shares your ambition is not optional—it is essential to survival and success.

38. Accelerating IND-Enabling Studies With Automated Bioanalysis Workflows 9/2/2025

    Reimagined as automation-first, bioanalysis shifts from being an Investigational New Drug (IND) bottleneck to a catalyst for innovation—helping companies move therapies forward with greater confidence.

39. Why Bioanalysis Needs To Break Free From Manual Bottlenecks 9/2/2025

    Bioanalysis remains one of the most persistent bottlenecks in drug development, with CRO's displaying inefficiencies that are no longer operational nuisances but strategic liabilities.

40. How Digital Twins Are Rewriting Clinical Trials 9/2/2025

    While the benefits of digital twins to accelerate clinical trials are undeniable, many questions about their use are still unanswered and go far beyond technology.